Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCQ | Q04759 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 9/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.40 |
| ▸ | DCTPP1 | Q9H773 | 2/20 | 0.38 |
| ▸ | SCD | O00767 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1814804 | 0.91 | LMNA (0.49) | PRKCQLMNAHTTHRH3DCTPP1 | |
| SCHEMBL22042049 | 0.84 | ACKR3 (0.45) | LMNAHTTDCTPP1SCD | |
| SCHEMBL22042051 | 0.84 | ACKR3 (0.45) | LMNAHTTDCTPP1SCD | |
| SCHEMBL15754487 | 0.80 | LMNA (0.50) | LMNAHTTDCTPP1SCD | |
| SCHEMBL1818131 | 0.79 | LMNA (0.36) | LMNAHTT | |
| SCHEMBL9005452 | 0.78 | PRKCQ (0.63) | PRKCQHRH4HRH3 | |
| SCHEMBL1816387 | 0.77 | SCD (0.54) | DCTPP1SCD | |
| SCHEMBL1814064 | 0.77 | LMNA (0.47) | LMNAHTTDCTPP1SCD | |
| SCHEMBL18890104 | 0.76 | HRH4 (0.46) | HRH4HRH3 | |
| SCHEMBL19489627 | 0.75 | KMO (0.57) | PRKCQHRH4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070299081-A1 | Heterocyclic Derivatives and Their Use as Mediators of Stearoyl-Coa Desaturase | XENON PHARMACEUTICALS INC. (CA) | 2007-12-27 | — | — | US | disclosed |
| CN-101084212-A | Heterocyclic derivatives and their use as mediators of stearoyl-coa desaturase | XENON PHARMACEUTICALS INC (CA) | 2007-12-05 | — | — | CN | disclosed |
| EP-1799668-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS MEDIATORS OF STEAROYL-COA DESATURASE | XENON PHARMACEUTICALS INC. (CA) | 2007-06-27 | — | — | EP | disclosed |
| WO-2006034338-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS MEDIATORS OF STEAROYL-COA DESATURASE | XENON PHARMACEUTICALS INC. (CA) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299081-A1 | Heterocyclic Derivatives and Their Use as Mediators of Stearoyl-Coa Desaturase | SCD, SCD5, NR1H2 | PRKCQ 1602/4885LMNA 475/4885HTT 2478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.